5-苯基-1H-吲哚-7-羧酸甲酯 | 860624-96-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-苯基-1H-吲哚-7-羧酸甲酯
• 英文名称: methyl 5-phenyl-1H-indole-7-carboxylate
• CAS: 860624-96-0
• 化学式: C₁₆H₁₃NO₂
• 分子量: 251.285
• InChiKey: NJSFLYKFAHEEET-UHFFFAOYSA-N

物化性质

• 沸点：
  468.8±33.0 °C(Predicted)
• 密度：
  1.225±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5-苯基-1H-吲哚-7-羧酸甲酯 在 N-碘代丁二酰亚胺 、 sodium hydride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.17h， 生成 methyl 3-iodo-5-phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole-7-carboxylate
  参考文献：
  名称：

  3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent

  摘要：

  I kappa B kinase beta (IKK beta or IKK2) is a key regulator of nuclear factor kappa B (NF-kappa B) and has received attention as a therapeutic target. Herein we report on the optimization of a series of 3,5-disubstituted-indole-7-carboxamides for oral activity. In doing so, we focused attention on potency, ligand efficiency (LE), and physicochemical properties and have identified compounds 24 and (R)-28 as having robust in vivo activity.

  DOI：

  10.1021/acsmedchemlett.8b00291
• 作为产物：
  描述：

  1-(1,1-dimethylethyl) 7-ethyl 2,3-dihydro-1H-indole-1,7-dicarboxylate 在 N-溴代丁二酰亚胺(NBS) 、 palladium diacetate 、 caesium carbonate 、 1,3-双(2,4,6-三甲基苯基)氯化咪唑 、 2,3-二氯-5,6-二氰基-1,4-苯醌 、 lithium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 氯仿 、 水 为溶剂， 反应 67.75h， 生成 5-苯基-1H-吲哚-7-羧酸甲酯
  参考文献：
  名称：

  3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent

  摘要：

  I kappa B kinase beta (IKK beta or IKK2) is a key regulator of nuclear factor kappa B (NF-kappa B) and has received attention as a therapeutic target. Herein we report on the optimization of a series of 3,5-disubstituted-indole-7-carboxamides for oral activity. In doing so, we focused attention on potency, ligand efficiency (LE), and physicochemical properties and have identified compounds 24 and (R)-28 as having robust in vivo activity.

  DOI：

  10.1021/acsmedchemlett.8b00291

文献信息

• [EN] INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS<br/>[FR] DERIVES D'INDOLE ET UTILISATION DE CEUX-CI COMME INHIBITEURS DE KINASE, NOTAMMENT DES INHIBITEURS DE IKK2
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005067923A1

  公开（公告）日：2005-07-28

  Indole carboxamide compounds of Formula (I): are provided as inhibitors of kinase activity, in particular IKK2 activity as well as compositions and medicaments containing them, for use in inflammatory and tissue repair disorders.

  提供式(I)的吲哚羧酰胺化合物作为激酶活性的抑制剂，特别是IKK2活性的抑制剂，以及含有它们的组合物和药物，用于炎症和组织修复障碍的治疗。
• Indole Derivatives and Use Thereof as Kinase Inhibitors in Particular Ikk2 Inhibitors
  申请人：Baldwin Ian Robert

  公开号：US20080269200A1

  公开（公告）日：2008-10-30

  Indole carboxamide compounds of Formula (I): are provided as inhibitors of kinase activity, in particular IKK2 activity as well as compositions and medicaments containing them, for use in inflammatory and tissue repair disorders.

  提供一种式子为(I)的吲哚羧酰胺化合物，作为激酶活性的抑制剂，特别是IKK2活性的抑制剂，并提供包含它们的组合物和药物，用于治疗炎症和组织修复性疾病。
• INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS IN PARTICULAR IKK2 INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1703905B1

  公开（公告）日：2008-11-12
• 3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent
  作者：Jeffrey K. Kerns、Jakob Busch-Petersen、Wei Fu、Jeffrey C. Boehm、Hong Nie、Michael Muratore、Ann Bullion、Guoliang Lin、Huijie Li、Roderick Davis、Xichen Lin、Ami S. Lakdawala、Rick Cousins、Rita Field、Jeremy Payne、David D. Miller、Paul Bamborough、John A. Christopher、Ian Baldwin、Ruth R. Osborn、John Yonchuk、Edward Webb、William L. Rumsey

  DOI：10.1021/acsmedchemlett.8b00291

  日期：2018.12.13

  I kappa B kinase beta (IKK beta or IKK2) is a key regulator of nuclear factor kappa B (NF-kappa B) and has received attention as a therapeutic target. Herein we report on the optimization of a series of 3,5-disubstituted-indole-7-carboxamides for oral activity. In doing so, we focused attention on potency, ligand efficiency (LE), and physicochemical properties and have identified compounds 24 and (R)-28 as having robust in vivo activity.